Salute e Benessere

Peripheral Artery Disease Market to Reach $10.8 billion, Globally, by 2035 at…

Prime determinants of growth Prime determinants of growth The peripheral artery disease market is expected to grow significantly owing to rise in the prevalence of peripheral artery disease, surge in the geriatric population, and rise in the adoption of minimal invasive procedures. Furthermore, technological advancement in peripheral artery disease treatment devices is expected to present significant growth opportunities in the peripheral artery disease market. Report coverage &...
PR Newswire
16/05/2024

Drug Screening Market Worth $19.5 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773 Browse in-depth TOC on "Drug Screening Market" 740 - Tables 62 - Figures 533 - Pages Drug Screening Market Scope: Services segment is expected to grow at the highest CAGR during the forecast period in 2024. On the basis of product & service segment, the drug...
PR Newswire
16/05/2024

Seegene and Springer Nature Announce Strategic Alliance

SEOUL, South Korea, May 16, 2024 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced on May 16th the signing of a strategic alliance agreement with Springer Nature, the publisher of the prestigious scientific journal, Nature. SEOUL, South Korea , May 16, 2024 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced on...
PR Newswire
16/05/2024

Brainomix Announces New Studies Further Validating the Impact of Brainomix 360…

Dr Michalis Papadakis, CEO and Co-Founder of Brainomix, said: "The studies presented this week at ESOC reflect our ongoing commitment to scientific excellence and our extensive academic collaborations with world-class research institutions, including the Mayo Clinic, the Rockefeller Institute at West Virginia University, and Boston Medical Center. These studies provide further validation that our AI-enabled technology can play a critical role in stroke care, helping clinicians make more…
PR Newswire
16/05/2024

Notification of managers' transactions

ANNOUNCEMENT NO. 267 Notification of managers' transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of CFO Niels Høy Nielsen in the attached PDF document. For further information, please contact:Niels Høy Nielsen, CFO...
Nasdaq GlobeNewswire
16/05/2024

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent…

Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEOPlan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Implementation of Restructuring Plan to Reduce Operating Costs Existing Investors Support the Company with Issuance of $1 million in Unsecured Convertible Notes BOSTON and LONDON, May16,...
Nasdaq GlobeNewswire
16/05/2024

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody®…

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the first Phase 3 program in hidradenitis suppurativa to use the higher clinical response level of HiSCR75 as the primary endpointThe topline primary endpoint readout at week 16, together with data on other endpoints, is expected as of mid-2025Program will evaluate sonelokimab for a total of 52 weeks, across VELA-1 and...
Nasdaq GlobeNewswire
16/05/2024

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational…

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive, fatal neurodegenerative condition CAMBRIDGE, Mass. and CARLSBAD, Calif., May16, 2024(GLOBE NEWSWIRE) --BiogenInc. (Nasdaq: BIIB) andIonis Pharmaceuticals, Inc...
Nasdaq GlobeNewswire
16/05/2024

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of…

In addition to the election of all nominees listed as directors in the management information circular, dated March 24, 2024, Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at eight and appointing the auditors for the Corporation for the ensuing year. In addition to the election of all nominees listed as directors in the management information circular, datedMarch 24,...
PR Newswire
16/05/2024

M42 receives Global Healthcare Accreditation Certification for Excellence in…

Since its inception, M42 has attracted patients from countries across the globe, including the UK, the US, Kuwait, India and Saudi Arabia. M42 leads the way in advanced medical procedures with state-of-the-art facilities such as Cleveland Clinic Abu Dhabi, Healthpoint, Moorfields and Imperial College London Diabetes Centre, among others. From robotic orthopedics to bariatric surgery, transplants, cardiac interventions, and IVF, M42 sets the standard for premier medical care globally. M42 now…
PR Newswire
16/05/2024

Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68…

Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the initial acceptance period is expected to occur on 23 May 2024Additional statutory acceptance period is expected to end on 30 May 2024 at 24:00 hours CESTTransaction strengthens the Novartis pipeline in oncology, adding pelabresib, a late-stage BET inhibitor for myelofibrosis and...
Nasdaq GlobeNewswire
16/05/2024

Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June…

The event will take place on Thursday, 6 June 2024 at Coloplast's Headquarters Holtedam 3, 3050 Humlebaek, Denmark from 11.30 - 18.00 CEST (Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2024 Meet the Management event. The event will be held in person at our headquarters in Humlebaek, Denmark, with the option to join us virtually for the plenary session. The purpose of the event is to provide participants with the...
Nasdaq GlobeNewswire
16/05/2024

Novo Nordisk Foundation, Rigshospitalet and CNIC press release: One in three…

"Atherosclerosis may develop from an early age and often remains 'silent', that is, without symptoms, for many years until it suddenly hits, for example with a heart attack," says Dr. Henning Bundgaard, Chief Physician and Professor at the Department of Cardiology at Rigshospitalet, Copenhagen, Denmark, and leader of the project. "In REACT, we hope to identify new means to detect atherosclerosis at earlier stages and at a younger age, that is during the 'silent' period."…
PR Newswire
16/05/2024

Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian…

The contract runs from 1 February 2025 to 31 January 2027. Navamedic expects that the renewed contract will contribute to a growth in the total antibiotic portfolio revenues of more than 20 percent. The contract runs from1 February 2025to31 January 2027. Navamedic expects that the renewed contract will contribute to a growth in the total antibiotic portfolio revenues of more than 20 percent. "We are proud to have been selected again as provider of antibiotics to Norwegian hospitals,...
PR Newswire
16/05/2024

Bioretec Ltd's business review January-March 2024: Controlled launch in the U.S…

January-March 2024 in brief January- March 2024in brief This business review is unaudited. This is Bioretec's first business review for the first quarter, and comparison period figures have not been published earlier. Key events during the reporting period Timo Lehtonen, CEO of Bioretec Ltd: "In the first quarter of 2024, our focus was on the production and distribution of our Activa product line as the U.S. market continued to utilize inventories of the RemeOs™ trauma...
PR Newswire
16/05/2024

Invitation to the presentation of Calliditas´s interim report January - March…

The presentation will be given in English. The presentation will be given in English. Link to the webcast : Calliditas Therapeutics Q1 Report 2024 (financialhearings.com) To participate via conference call please register via this link:https://conference.financialhearings.com/teleconference/?id=50047214 After registration, you will receive a phone number and a conference ID to log in to the conference call. Via the telephone conference, there is an opportunity to ask oral...
PR Newswire
16/05/2024

LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of…

LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants Groundbreakingin vivostudies will be progressed to explore the impact of IMAN cell therapies in solid tumour and immunology models uniquely available at the Saeb-Parsy Lab at the University of Cambridge London, 16 May 2024– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech company about to start clinical trials for its first-in-class...
Nasdaq GlobeNewswire
16/05/2024

XRP Healthcare Sponsors The Ehlers-Danlos Society, with Vital Support via its…

Dedicated to raising awareness and support for individuals living with any of the types ofEhlers-Danlos syndrome ( EDS) or hypermobility spectrum disorders (HSD), this event will be a beacon of hope and solidarity for the EDS and HSD community. EDS and HSD are a group of heritable connective tissue disorders characterized by joint hypermobility, widespread musculoskeletal pain, multiple other concerns termed comorbidities, and, in EDS, fragile body tissues that more easily scar,...
PR Newswire
16/05/2024

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China…

Allschwil, Switzerland, May 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba ®(isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch,...
Nasdaq GlobeNewswire
16/05/2024

Zealand Pharma Announces Financial Results for the First Quarter of 2024

Company announcement - No. 26 / 2024 Zealand Pharma Announces Financial Results for the First Quarter of 2024Strong performance in the first quarter of 2024 paving the way for important data read-outs across differentiated obesity assets in the second quarter. Strong topline results announced in Boehringer Ingelheim Phase 2 clinical trial for survodutide in MASHPDUFA date for glepaglutide in SBS set by US FDA for December 22, 2024 PDUFA date for dasiglucagon in CHI for up to...
Nasdaq GlobeNewswire
16/05/2024

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I…

Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) At week 24, 100% of CT-388 treated participants achieved >5% weight loss, 70% achieved >15% and 45% achieved >20% weight loss In a subgroup with pre-diabetes at baseline, CT-388 treatment normalised glycemia in all patients, indicating its strong impact on glucose homeostasisNo new or...
Nasdaq GlobeNewswire
16/05/2024

Endo to Announce First-Quarter 2024 Financial Results for Endo International plc

Please join 10 minutes prior to the scheduled start time. Please join 10 minutes prior to the scheduled start time. About EndoEndo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn. Logo -...
PR Newswire
15/05/2024

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22…

Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST PARIS and CAMBRIDGE, Mass., May15, 2024(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO – NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the first quarter of 2024 on May 22, 2024, before the US and EU...
Nasdaq GlobeNewswire
15/05/2024

Galapagos and Blood Centers of America announce strategic collaboration to…

BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centersCollaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access to potentially life-saving CAR-T treatmentsImportant milestone for Galapagos' U.S. expansion strategy, supporting upcoming pivotal trials and potential future commercial manufacturing of CAR-T...
Nasdaq GlobeNewswire
15/05/2024
Altri  Comunicati